ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma.

ABSTRACT:

Background

Previous studies have shown that aldolase B (ALDOB) might play controversial roles in multiple types of cancer, which could act as a cancer-promoting factor or a cancer-inhibiting factor depending on the subtype of the cancer. However, the role of ALDOB in clear cell renal cell carcinoma (ccRCC) patients has not been clearly elucidated. Therefore, this study aimed to comprehensively explore the expression level, prognostic value, functional enrichment, immune infiltration, and N6-methyladenosine (m6A) modification of ALDOB in ccRCC patients.

Methods

A total of 1,070 ccRCC tissues and 409 normal tissues from the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) database, and the ArrayExpress database were enrolled to evaluate the expression lev

SUBMITTER: Shao Y 

PROVIDER: S-EPMC10170270 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature